Compare Equinox Gold Corp. Common Shares (EQX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinox Gold Corp. Common Shares vs Tango Therapeutics Inc. — how do they compare? Equinox Gold Corp. Common Shares trades at $10.57 (market cap $12.03B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Equinox Gold Corp. Common Shares is far larger — about 3.2× Tango Therapeutics Inc.'s market cap, and Equinox Gold Corp. Common Shares pays a 0.51% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| EQX | TNGX | |
|---|---|---|
Market Cap | $12.03B | $3.74B |
Volume | 12,695,148 | 3,438,781 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $32.90 |
52-Week Low | $8.62 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.13B | $2.76B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinox Gold (EQX) trades at $10.85, down 3.12% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $1.82B revenue and $221M net income, and projects significant growth in 2026 to $2.9B revenue. Recent news highlights the completion of the Orla Mining merger, positioning EQX as a major North American gold producer with a path to 2 million ounces of annual production.
The outlook is positive due to transformative growth from the Orla acquisition, increased production guidance, and a 50% dividend hike. Risks include execution of mine expansions and gold price volatility. With a 100% buy rating from one analyst, the stock appears undervalued relative to its growth pipeline, though recent earnings misses warrant monitoring.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinox Gold Corp. Common Shares
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
